[…] of genetic tests assessing disease-associated chromosomal abnormalities. Their lead indication is Facioscapulohumeral Muscular Dystrophy ( FSHD). FSHD is one of the most prevalent forms of muscular dystrophy and affects approximately […]
New genetic test being developed for FSHD
Patient-Focused Drug Development Meeting for FSHD
The FSHD Society announced today that the U.S. Food and Drug Administration (FDA) has approved its application to hold an externally led Patient-Focused Drug Development (EL-PFDD) meeting on facioscapulohumeral muscular […]
A giant of FSHD research shares his “regrets”
In his keynote lecture from this year’s International Research Congress on FSHD, held virtually on June 25-26, George Padberg, MD, regarded as the father of modern FSHD research, shared observations […]
FDA Fast Track Designation for Avidity’s FSHD therapeutic
[…] granted Fast Track designation to AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy ( FSHD). FSHD is a serious, rare, hereditary muscle-weakening condition marked by life-long, progressive loss of […]
World FSHD Day backstory
Italian brothers’ ordeal sparks a global movement As we approach our third annual World FSHD Day this June 20th, and the international FSHD community plans to flood their social channels […]